help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maccagnan, P.
Right arrow Articles by Abucham, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maccagnan, P.
Right arrow Articles by Abucham, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DEXAMETHASONE
*LEVOTHYROXINE
*TESTOSTERONE

Journal of Clinical Endocrinology & Metabolism, Vol 80, 2190-2197, Copyright © 1995 by Endocrine Society


ARTICLES

Conservative management of pituitary apoplexy: a prospective study

P Maccagnan, CL Macedo, MJ Kayath, RG Nogueira and J Abucham
Department of Medicine, Escola Paulista de Medicina, Sao Paulo, Brazil.

A prospective study was conducted to evaluate the usefulness and limitations of conservative treatment in patients with pituitary apoplexy. Twelve patients presenting sudden headache, visual impairment, or ophthalmoplegia had the diagnosis of pituitary apoplexy established by computerized tomographic scans. Initially, 11 patients received iv dexamethasone (2.0-16.0 mg/day). Surgery was indicated when dexamethasone failed to improve visual or consciousness impairment. Among the 7 patients who were treated conservatively, ophthalmoplegia recovered completely in 6 and improved in 1. Follow-up computerized tomographic scans showed resolution of the tumor in 4 patients and residual masses in 3 patients who were treated conservatively. Five patients had surgery and experienced improvement of vision and consciousness. Follow-up computerized tomographic scans showed residual masses in all surgical patients. Recurrences were observed in 2 patients, one in each group. The prevalence of pituitary deficiencies in the conservative group (9 of 17) was similar to that of the surgical group (3 of 14), but when only patients whose tumors were resolved by the apoplexy were analyzed, a significantly higher prevalence (8 of 12) was observed (P = 0.02). A retrospective analysis of presenting clinical and computerized tomography data on the basis of the response to dexamethasone showed that visual impairment did not improve during treatment with dexamethasone, whereas the presence of a large hypodense area within the tumor predicted complete tumor resolution. These results support conservative management of pituitary apoplexy in patients who are selected on the basis of clinical and tomographic findings.


This article has been cited by other articles:


Home page
J Intensive Care MedHome page
R. N. Nawar, D. AbdelMannan, W. R. Selman, and B. M. Arafah
Analytic Review: Pituitary Tumor Apoplexy: A Review
J Intensive Care Med, March 1, 2008; 23(2): 75 - 90.
[Abstract] [PDF]


Home page
Postgrad. Med. J.Home page
T Kearney and C Dang
Diabetic and endocrine emergencies
Postgrad. Med. J., February 1, 2007; 83(976): 79 - 86.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao
Advances in the Treatment of Prolactinomas
Endocr. Rev., August 1, 2006; 27(5): 485 - 534.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Goswami, N. Kochupillai, P. A. Crock, A. Jaleel, and N. Gupta
Pituitary Autoimmunity in Patients with Sheehan's Syndrome
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4137 - 4141.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. Ben-Jonathan and R. Hnasko
Dopamine as a Prolactin (PRL) Inhibitor
Endocr. Rev., December 1, 2001; 22(6): 724 - 763.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J R Anderson, N Antoun, N Burnet, K Chatterjee, O Edwards, J D Pickard, and N Sarkies
Neurology of the pituitary gland
J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 703 - 721.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society